MediciNova MN-001 Trial Hits HDL-C, Misses on Liver Fat

# MediciNova MN-001 Trial Hits HDL-C, Misses on Liver Fat

MediciNova, Inc. (NASDAQ: MNOV) announced on Sept. 28, 2026, that its Phase 2 MN-001-NATG-202 trial of MN-001 (tipelukast) produced a statistically significant 5.7 mg/dL separation in HDL cholesterol versus placebo at Week 24 (p=0.0048) and a 30.96 mg/dL greater triglyceride reduction at Week 4 (p=0.015). The 40-patient study in hypertriglyceridemia and NAFLD associated with type 2 diabetes missed significance on liver fat (p=0.2438) and Week 24 triglycerides (p=0.113).

Context — Why This Readout Matters Now

The company framed the trial as a proof-of-concept, exploratory study, and its own preliminary review of the topline data concluded that efficacy should be evaluated in a larger study. That is the company's own characterization, not an outside assessment.

The report gives one direct internal comparable: the earlier MN-001-NATG-201 clinical trial. MediciNova said the direction of change in triglycerides, HDL-C and HDL-P was consistent with that prior trial and with preclinical in-vitro mechanism-of-action work. No numerical results from NATG-201 appear in the report.

The readout lands on a pipeline where MN-001 already had one Phase 2 trial completed in idiopathic pulmonary fibrosis and a second Phase 2 trial in NAFLD described as ongoing. MediciNova said it has 11 programs in clinical development and that its lead asset, MN-166 (ibudilast), is in Phase 3 for ALS and degenerative cervical myelopathy and Phase 3-ready for progressive multiple sclerosis.

The commercial backdrop is the overlap between insulin resistance, dyslipidemia and fatty liver. The company described NAFLD as a hepatic complication of insulin resistance frequently associated with T2DM and dyslipidemia, and said hypertriglyceridemia results from increased hepatic lipid synthesis alongside impaired clearance of triglyceride-rich lipoproteins.

The trigger for the announcement is simply the unblinding and topline review of a 24-week treatment period. No regulatory catalyst, partnership or financing event is attached to the release.

Data — What the Numbers Show

Every figure below is from the company's topline disclosure, with placebo arms shown for comparison.

Endpoint	MN-001	Placebo	Between-group	p-value
TG, Week 24	-45.8 mg/dL (-21.78%)	-14.4 mg/dL (-6.97%)	-31.4 mg/dL	0.113
TG, Week 4	-54.7 mg/dL (-26.05%)	-23.8 mg/dL (-11.54%)	-30.96 mg/dL	0.015
Liver fat (CAP)	-14.1 dB/m (-4.24%)	-4.3 dB/m (-1.27%)	-9.7 dB/m	0.2438
HDL-C	+3.3 mg/dL (+8.39%)	-2.4 mg/dL (-6.23%)	+5.7 mg/dL	0.0048
HDL-P	+3.62 µmol/L (+11.80%)	-0.9 µmol/L (-3.00%)	+4.52 µmol/L	0.018
Body weight	-4.91 lb (-2.28%)	-0.55 lb (-0.25%)	-4.36 lb	0.082

The pattern is that the two lipid-particle measures cleared significance while the two directional measures did not. HDL-C rose in the MN-001 arm while falling in placebo, a divergence rather than a shared drift. The same split appears in HDL-P.

Triglycerides tell the opposite story over time. The Week 4 separation was significant; by Week 24 the placebo arm had also fallen, and the between-group gap narrowed to a level the study could not distinguish from chance at conventional thresholds.

Liver fat moved in the right direction on the FibroScan® controlled attenuation parameter, 14.1 dB/m in the treatment arm against 4.3 dB/m in placebo, but the 9.7 dB/m advantage did not reach statistical significance in a 40-patient sample.

Analysis — What It Means for Markets and Sectors

The readout splits cleanly. A statistically significant HDL-C and HDL-P result is a lipid-modification signal, while the triglyceride and liver-fat results are directional only. For a small-cap clinical-stage biotech, that combination tends to be read as mechanism validation without an obvious registrational endpoint.

The exposure sits first in MediciNova itself, where the equity case rests on a pipeline the company says spans 11 programs across two compounds. Any repricing tied to this readout would be a judgment on MN-001's place in that pipeline rather than on near-term revenue, because the report discloses no approved product, no partner and no commercialization timeline for MN-001 in this indication.

Second-order read-through runs to the adjacent metabolic and fatty-liver development space, where competitors are pursuing overlapping patient populations of T2DM with dyslipidemia and hepatic steatosis. The report names no competitor and gives no comparative data, so the readthrough is thematic rather than quantitative.

The central limitation is sample size and design. Forty patients over 24 weeks is enough to detect a large lipid-particle effect and too small to resolve a liver-fat effect of the size observed, which is why the company itself said efficacy should be evaluated in a larger study. The Week 24 triglyceride result also raises a duration question: the effect was strongest early and attenuated as placebo caught up.

Positioning follows from that. Long-side interest in clinical-stage metabolic names tends to concentrate on assets with a clean registrational path; this readout supplies mechanism evidence and leaves the endpoint question open, which is the profile that keeps generalist flow out until the next study design is disclosed.

Outlook — What to Watch Next

The company said it will continue detailed analyses of the study data and assess the next stage of clinical development, including the appropriate patient population, endpoints and sample size. It gave no date for that decision.

MediciNova also said a second Phase 2 trial of MN-001 in NAFLD is ongoing. Results from that trial, when disclosed, would be the next independent test of the compound in a liver-focused population.

The MN-166 programs are the other scheduled catalysts the report identifies: Phase 3 in ALS and degenerative cervical myelopathy and Phase 3-ready status in progressive multiple sclerosis. The company disclosed no readout dates.

On the financing side, the report's forward-looking language flags risks around obtaining future partner or grant funding and raising sufficient capital when needed. Any development-stage decision that expands trial size carries a funding implication, though the company attached no figure to it.

Frequently Asked Questions

What does the MediciNova MN-001 trial result mean for retail investors?

It means the trial produced two statistically significant lipid-particle results and two directional ones. HDL-C separated from placebo by 5.7 mg/dL at p=0.0048 and HDL-P by 4.52 µmol/L at p=0.018. Triglycerides at Week 24 (p=0.113), liver fat (p=0.2438) and body weight (p=0.082) did not reach significance. The company called the study exploratory and said efficacy needs a larger trial.

What happens next for MediciNova and MN-001?

The company said it will run detailed analyses of the study data and then assess the next stage of clinical development, covering patient population, endpoints and sample size. It did not give a timeline. Separately, it said a second Phase 2 trial of MN-001 in NAFLD is ongoing, and its MN-166 programs remain in or near Phase 3 across neurological indications.

Why did the triglyceride result change between Week 4 and Week 24?

At Week 4, MN-001 cut triglycerides by 54.7 mg/dL versus 23.8 mg/dL for placebo, a 30.96 mg/dL gap that was significant at p=0.015. By Week 24, MN-001's reduction reached 45.8 mg/dL while placebo's reached 14.4 mg/dL, narrowing the gap to 31.4 mg/dL at p=0.113. The placebo arm's own decline widened over the treatment period.

Bottom Line

MediciNova's MN-001 validated two lipid-particle endpoints but left liver fat and durable triglyceride benefit unproven in a 40-patient study.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.